Pyoderma gangrenosum (PG) is a rare, debilitating, inflammatory skin disease associated with a variety of systemic diseases. Because of its rarity, PG is treated with miscellaneous immunosuppressive agents as there is no US Food and Drug Administration-approved standardized treatment approach. We present four patients with PG treated with tofacitinib in the context of the six existing cases in the literature. Tofacitinib appeared to be beneficial in the small sample of patients (n = 10) who failed an average of four other systemic therapies. The majority of patients had classic PG located on the legs (80%, 8/10), while 20% of cases (2/10) were peristomal. The most common comorbidity was inflammatory bowel disease (78%, 7/9). There were no negative treatment results and 40% (4/10) of patients had complete healing of their ulcers, while the other 60% (6/10) had marked clinical improvement. From our observation, tofacitinib appears to be a promising steroid-sparing adjuvant treatment in patients with refractory PG who have failed on other systemic therapies.
Itchy skin, a symptom of various diseases, present in 54.4 % of patients with skin pathologies, is a rather difficult task when choosing a therapy.Material and methods. Under observation were 45 patients (27 women and 18 men) with various dermatoses, accompanied by itching. All patients received Neotanin therapy (cream and spray) with standard topical therapy. Efficiency assessment was carried out taking into account the indices Prurindex, BRS, dermatological status indices for each nosology (SCORAD, EASI, PASI), and DIC.Results. In patients with idiopathic skin itching, Prurindex decreased by 100 % by the end of 3rd weeks, BRS – by 96.8 %. In atopic dermatitis, the SCORAD index decreased by 78.3 %, BRS index reduced by 91.9 %, Prurindex index decreased by 95.4 %. With eczema, the EASI index decreased by 96.1 %, the BRS and Prurindex index were reduced by 100 %. In psoriasis, the PASI index decreased by 86.5 %, BRS index – by 90.8 %, Prurindex index – by 94.2 %.Conclusions. The use of the topical Neotanin as monotherapy for idiopathic pruritus, as a part of comprehensive treatment for atopic dermatitis, eczema, psoriasis, significantly improves the quality of life of patients.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.